A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis Source: Eur Respir J 2006; 27: 460-469 Year: 2006
Bleomycin induced lung fibrosis in mice is attenuated by a new somatostatin analog Source: Annual Congress 2006 - Matrix remodelling at the interface of lung fibrosis and emphysema Year: 2006
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2005; 25: 708-714 Year: 2005
The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 827s Year: 2006
Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012
Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats Source: Eur Respir J 2001; 17: 1228-1235 Year: 2001
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020
Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018
Effect of simvastatin on bleomycin induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2002; 20: Suppl. 38, 487s Year: 2002
HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019
The novel oligonucleotide therapeutics PK-7010 for TGF-ß1 ameliorates bleomycin-induced pulmonary fibrosis in mice Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013